Provided by Tiger Trade Technology Pte. Ltd.

Supernus Pharmaceuticals

44.03
+0.29000.66%
Post-market: 44.030.00000.00%19:30 EDT
Volume:445.94K
Turnover:19.62M
Market Cap:2.56B
PE:-23.00
High:45.05
Open:44.42
Low:43.67
Close:43.74
52wk High:59.68
52wk Low:42.45
Shares:58.04M
Float Shares:51.67M
Volume Ratio:0.81
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9145
EPS(LYR):-0.6829
ROE:-10.49%
ROA:0.39%
PB:2.48
PE(LYR):-64.48

Loading ...

Apr 07, 2026

Major Issues Report

Form 8-K - Current report
Mar 18, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 16, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 13, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 12, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 10, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 09, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 09, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 06, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 05, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 03, 2026

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 24, 2026

Major Issues Report

Form 8-K - Current report
Feb 24, 2026

Major Issues Report

Form 8-K - Current report
Feb 19, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 12, 2026

Major Issues Report

Form 8-K - Current report
Jan 28, 2026

Major Issues Report

Form 8-K - Current report
Dec 19, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 06, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 05, 2025

Major Issues Report

Form 8-K - Current report
Oct 21, 2025

Major Issues Report

Form 8-K - Current report